- increased T cell number / IMPC
- hyperactivity / IMPC
- decreased hemoglobin content / IMPC
- abnormal glucose homeostasis / IMPC
- thrombocytosis / IMPC
- decreased hematocrit / IMPC
- decreased circulating cholesterol level / IMPC
- decreased IgG3 level / IMPC
- decreased mature B cell number / IMPC
- decreased circulating free fatty acids level / IMPC
- increased IgM level / IMPC
- increased IgG1 level / IMPC
- decreased circulating triglyceride level / IMPC
- decreased bone mineral density / IMPC
- increased IgG2b level / IMPC
- decreased erythrocyte cell number / IMPC
C57BL/6N-Plcg2em1(IMPC)Wtsi/WtsiCnbc
Status | Available to order |
EMMA ID | EM:13892 |
Citation information | RRID:IMSR_EM:13892 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
International strain name | C57BL/6N-Plcg2em1(IMPC)Wtsi/WtsiCnbc |
Alternative name | |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | Plcg2em1(IMPC)Wtsi |
Gene/Transgene symbol | Plcg2 |
Information from provider
Provider | Wellcome Trust Sanger Institute |
Provider affiliation | Wellcome Trust Sanger Institute |
Genetic information | This mouse line originates from CRISPR zygote microinjection. For further details see the project page at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
Animals used for archiving | heterozygous C57BL/6N males |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- PLCG2-associated antibody deficiency and immune dysregulation / Orphanet_300359
- Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation / Orphanet_324530
IMPC phenotypes (gene matching)
MGI phenotypes (gene matching)
- abnormal trabecular bone morphology / MGI
- abnormal foot pad morphology / MGI
- spleen hyperplasia / MGI
- dermatitis / MGI
- internal hemorrhage / MGI
- abnormal humoral immune response / MGI
- arrested B cell differentiation / MGI
- decreased IgM level / MGI
- abnormal inflammatory response / MGI
- abnormal lymphatic vessel morphology / MGI
- premature death / MGI
- abnormal B cell differentiation / MGI
- abnormal dendritic cell physiology / MGI
- increased susceptibility to viral infection / MGI
- abnormal B cell physiology / MGI
- chronic inflammation / MGI
- glomerulonephritis / MGI
- increased pre-B cell number / MGI
- decreased susceptibility to induced arthritis / MGI
- osteoarthritis / MGI
- decreased osteoclast cell number / MGI
- impaired natural killer cell mediated cytotoxicity / MGI
- decreased B cell proliferation / MGI
- increased B cell proliferation / MGI
- immune system phenotype / MGI
- abnormal dendritic cell morphology / MGI
- decreased B-1a cell number / MGI
- decreased follicular B cell number / MGI
- increased pro-B cell number / MGI
- decreased transitional stage B cell number / MGI
- decreased B-2 B cell number / MGI
- decreased mature B cell number / MGI
- abnormal osteoclast differentiation / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interferon-gamma secretion / MGI
- increased B cell apoptosis / MGI
- increased trabecular bone thickness / MGI
- decreased platelet aggregation / MGI
- increased transitional stage T2 B cell number / MGI
- abnormal dendritic cell chemotaxis / MGI
- abnormal NK cell physiology / MGI
- increased trabecular bone volume / MGI
- chylous ascites / MGI
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).